Company news

Telix Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Telix Submits NDA for New Prostate Cancer Imaging Agent

May 26, 2024

Telix Annual General Meeting - Presentation

May 22, 2024

Telix Annual General Meeting - Chairman and CEO Addresses

May 22, 2024

Telix Completes Proof-of-Concept Study for Alpha Therapy

May 20, 2024

Telix has Filed Registration Statement for Proposed US IPO

May 19, 2024

Telix Reports Q1 2024 Financial Performance

May 17, 2024

Telix Completes Acquisition of QSAM

May 2, 2024

Telix Q1 2024 Revenue and Business Update

April 17, 2024

TLX101-CDx (Pixclara) Granted FDA Fast Track Designation

April 15, 2024

Telix Completes Acquisition of ARTMS

April 11, 2024

Telix Completes Acquisition of IsoTherapeutics

April 8, 2024

Telix General Meeting Presentation

April 4, 2024

Telix General Meeting Chairman and CEO Addresses

April 4, 2024

Telix to Acquire ARTMS (Isotope Production Platform)

March 4, 2024

Presentation to Accompany ARTMS Acquisition

March 4, 2024

Telix to Acquire IsoTherapeutics (US R&D and Manufacturing)

February 26, 2024

2023 Full Year Results Presentation

February 22, 2024

Appendix 4E and 2023 Annual Report

February 22, 2024

2023 Full Year Results Release

February 22, 2024

Telix Acquires QSAM and its Bone Cancer Targeting Platform

February 7, 2024

Presentation to Accompany QSAM Acquisition

February 7, 2024

JP Morgan Healthcare Conference Presentation

January 8, 2024

JP Morgan Healthcare Conference and Trading Update

January 8, 2024

Telix Plans U.S. Registered Public Offering and Listing

January 4, 2024

Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging

December 18, 2023

Telix Announces Proposed Acquisition of QSAM Biosciences

November 13, 2023

First Patient Dosed in Ph III ProstACT GLOBAL Therapy Study

November 12, 2023

Telix Completes Acquisition of Lightpoint Medical

November 1, 2023

ProstACT SELECT Study of TLX591 Positive Interim Readout

October 18, 2023

Q3 2023 Business Update to Accompany Quarterly Results

October 18, 2023

Activities Report and Appendix 4C - September 2023 Quarter

October 18, 2023

1H 2023 Results Release

August 23, 2023

1H 2023 Results Presentation

August 23, 2023

1H 2023 Appendix 4D and Interim Report

August 23, 2023

First Patient Dosed in Phase 3 Illuccix China Study

August 10, 2023

Q2 2023 Business Update to Accompany Quarterly Results

July 19, 2023

Activities Report and Appendix 4C - June 2023 Quarter

July 19, 2023

Lightpoint Acquisition to Expand Telix Urologic Pipeline

June 21, 2023

Phase II study for indication expansion of TLX250-CDx doses

June 18, 2023

Annual General Meeting - Presentation

May 24, 2023

Annual General Meeting - Chairman and CEO Addresses

May 23, 2023

ZIRCON Data Presented at AUA Confirms Efficacy in 2cm Masses

April 30, 2023

Presentation to Accompany AI Development Program Update

April 26, 2023

Telix Accelerates AI Development with Dedicaid Acquisition

April 26, 2023

Q1 2023 Business update to accompany quarterly results

April 17, 2023

Appendix 4C and Activities Report - March 2023 Quarter

April 17, 2023

Telix Preclinical Development of Radiolabelled Olaratumab

April 16, 2023

Illuccix European Marketing Authorisation Application Update

April 2, 2023

FDA approval of expanded indication of Illuccix in the US

March 15, 2023

2022 Full Year Results Presentation

February 27, 2023

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 57 decks. Every deck is listed under its year.